COPD Chronic obstructive pulmonary disease
Conditions
Interventions
Patients receive a single dose of Imidafenacin0.1mg, and then washout 7-14 days, patients receive a placebo.
Patients receive a placebo, and then washout 7-14 day, patients receive a single dose of Im
Sponsors
Graduate School of Medical and Dental Sciences Kagoshima University Pulmonary Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Male and female Japanese patients aged 40 years or older with clinically diagnosed stable COPD. FEV1.0/FVC<0.70 It does not matter for the stage of a disease. A smoking history more than 10 pack years. The patient who can acquire a document agreement from the person himself.
Exclusion criteria
Exclusion criteria: Patients were excluded from participation if they corresponds to a contraindicated matter of imidafenacin(urinary retention, bowel obstruction, paralytic ileus, glaucoma, myasthenica gravis). The patient who is complicated with chronic respiratory desease except COPD. Patient having allergy to anticholinergic agent. The patient who has difficulty perform of the spirometry. In addition, the patient who judged that the examination medical attendant was inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pulmonary function test | — |
Countries
Japan
Contacts
Public ContactIkkou higashimoto
Graduate School of Medical and Dental Sciences Kagoshima University Pulmonary Medicine
Outcome results
None listed